Xgeva推荐使用量多少？

Denosumab is a commonly used anti-cancer drug. It is clinically used to treat unresectable giant cell tumors of bone in adults and skeletally mature adolescents; hypercalcemia caused by malignant tumors; to increase bone mass in patients with high risk of fractures, including androgen castration therapy for non-metastatic prostate cancer or adjuvant therapy with aromatase inhibitors for breast cancer; to prevent bone-related events in patients with bone metastases from solid tumors; to treat osteoporosis in postmenopausal women with a high risk of fractures, but not in patients with multiple myeloma or other leukemias. Its therapeutic effects are also recognized. In addition to the effects of a drug itself, the usage and dosage during taking are also the key to the efficacy. Therefore, patients need to strictly follow the doctor’s instructions while taking it.

Recommended usage and dosage of Xgeva denosumab: (1) Xgeva denosumab can only be injected subcutaneously, not intravenous infusion, intramuscular infusion or intradermal injection. (2) Solid tumor bone metastasis: 120mg once every 4 weeks, injected subcutaneously in the upper arm, thigh or abdomen. (3) Giant cell tumor of bone: 120 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. (4) Administer calcium and vitamin D appropriately to prevent hypocalcemia. (5) Malignant hypercalcemia: 20 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen. 

There are currently no studies on the effectiveness and safety of this product in children, so the use of Xgeva denosumab in children is not recommended.

  There is no need to adjust the dosage for the elderly and patients with renal insufficiency. For patients with severe renal insufficiency and those undergoing dialysis treatment, blood calcium monitoring should be carried out, and calcium and vitamin D supplementation should be paid attention to.

It is not yet clear whether denosumab can be excreted in breast milk. Breast-feeding women should weigh the importance of this product and choose to discontinue the drug or stop breastfeeding.